Research
Hormonal
GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE) and slow chronic kidney disease progression in Type 2 Diabetes, but evidence for improving heart failure outcomes is mixed or insufficient.
If you have Type 2 Diabetes and high heart risk or kidney issues, GLP-1 agonists (like Ozempic, Trulicity, or Victoza) are highly recommended to prevent heart attacks and protect kidneys. However, they are not currently proven to treat existing heart failure. If you struggle with injections, ask about oral semaglutide.
GoodQualifiesHIGH confidence
Globally, GLP-1 RAs had a neutral effect on risk for HF... There is insufficient evidence on the benefit of GLP-1 RAs in patients with HF.
Why this rating
Strong evidence for MACE/CKD from LEADER, SUSTAIN-6; weak/mixed for HF from LIVE, FIGHT trials.
Source
Cardiorenal syndrome and diabetes: an evil pairing
Ana Belén Fernández et al. · Frontiers in Cardiovascular Medicine · 2023
DOI 10.3389/fcvm.2023.1185707
narrative_reviewCited 17×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →